NCT03723252View on ClinicalTrials.gov

Dapagliflozin Efficacy and Action in NASH

PHASE3CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

March 22, 2024

Study Completion Date

March 28, 2024

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Dapagliflozin

Participants will receive dapagliflozin 10mg po qd

DRUG

Placebo

Participants will receive placebo po qd

Trial Locations (1)

510515

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT03723252 - Dapagliflozin Efficacy and Action in NASH | Biotech Hunter | Biotech Hunter